IP Library Granted Patent US 6,926,912
Granted Patent B1
US 6,926,912 · App. 09/508,923 · Granted Aug 9, 2005

Metal compounds, mixed or sulphated, as phosphate binders

Assignee: Ineos Silicas Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,926,912
App. No.
09/508,923
Granted
Aug 9, 2005
Kind
B1
Abstract

A non-aluminum containing mixed metal compound for pharmaceutical use, which may, for example, be a mixed metal hydroxy carbonate containing magnesium and iron, and may have a hydrotalcite structure, preferably a non-aged hydrotalcite structure. Other metals, including, for example, calcium, lanthanum and cerium, may also be used. Metal sulphate compounds, especially calcium sulphate, lanthanum sulphate and/or cerium sulphate, compounds are also useful. The mixed metal compounds have a phosphate binding capacity of at least 30%, by weight, based on the test methods 1, 2 or 3, described in the specification, over a pH range from 3 to 7, such as from 2 to 8. The compound is especially useful in the treatment of hyperphosphataemia.

Claims (16)

1. A method for treating hyperphosphataemia, in an animal in need thereof, which comprises administering to said animal, a therapeutically effective amount of a solid mixed metal compound having a phosphate binding capacity, and comprising the compound obtained as a precipitate from a solution of a mixture of metallic salts, free from aluminum, and containing iron (III) and at least one additional metal selected from the group consisting of magnesium, calcium, lanthanum and cerium, said compound having a phosphate binding capacity of at least 30%, as measured by any of the following tests methods (1) or (2), over a pH range of from 3 to 7;

(1) adding 1 gram of said solid mixed metal compound to 25 ml of 40 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature of 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate in the supernatant thus produced;

(2) adding 1 gram of said solid mixed metal compound to 25 ml of 20 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature for 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate 1 the supernatant thus produced.

2. Method according to claim 1 wherein the solid mixed metal compound containing hydroxyl ions and/or carbonate ions.

3. Method according to claim 2 , wherein the solid mixed metal compound further contains sulphate, chloride, oxide or mixtures thereof.

4. The method of claim 1 wherein said animal is a human.

5. A method for treating hyperphosphataemia, in an animal in need thereof, which comprises administering to said animal, a therapeutically effective amount of a solid mixed metal oxide compound having phosphate binding capacity, and comprising the compound obtained as a precipitate from a solution of a mixture of metallic salts, free from aluminum, and containing iron (III) and at least one additional metal selected from the group consisting of magnesium, calcium, lanthanum and cerium, said compound having a phosphate binding capacity of at least 30%, as measured by any of the following test methods (1) or (2), over a pH range of from 2 to 8;

(1) adding 1 gram of said solid mixed metal compound to 25 ml of 40 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature of 30 minutes centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate in the supernatant thus produced;

(2) adding 1 gram of said solid mixed metal compound to 25 ml of 20 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature for 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate in the supernatant thus produced.

6. Method according to claim 5 , wherein the solid mixed metal compound contains hydroxyl ions and/or carbonate ions.

7. Method according to claim 6 , wherein the solid mixed metal compound further contains sulphate, chloride, oxide or mixture thereof.

8. The method of claim 5 wherein said animal is a human.

9. A method for treating hyperphosphataemia, in an animal in need thereof, which comprises administering to said animal, a therapeutically effective amount of a solid mixed metal compound having phosphate binding capacity, and comprising a hydroxy carbonate containing iron (III) and magnesium metals, further containing sulphate, chloride, oxide or mixtures thereof and free from aluminum, and having a phosphate binding capacity of at least 30% by weight, as measured by any of the test methods (1) or (2), over a pH range of 2 to 8;

(1) adding 1 gram of said solid mixed metal compound to 25 ml of 40 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature of 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate in the supernatant thus produced;

(2) adding 1 gram of said solid mixed metal compound to 25 ml of 20 mmol 1 −1 sodium phosphate buffer solution, homogenizing and gently agitating at room temperature for 30 minutes, centrifuging at 3000 rpm for 5 minutes, filtering through 0.22 μm millipore filter and measuring the soluble phosphate in the supernatant thus produced.

10. The method of claim 9 wherein said animal is a human.

Assignments (9)
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Sep 2, 2015
From: CYTOCHROMA CAYMAN ISLANDS, LTD.
To: OPKO IP HOLDINGS, INC.
Reel/Frame 036526/0675 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Sep 2, 2015
From: CYTOCHROMA DEVELOPMENT INC.
To: CYTOCHROMA CAYMAN ISLANDS, LTD.
Reel/Frame 036526/0690 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Sep 2, 2015
From: OPKO HOLDINGS, INC.
To: OPKO IRELAND GLOBAL HOLDINGS, LTD.
Reel/Frame 036526/0699 →
CONFIRMATORY PATENT RIGHTS AGREEMENT Recorded Sep 2, 2015
From: OPKO IP HOLDINGS, INC.
To: OPKO HOLDINGS, INC.
Reel/Frame 036526/0708 →
SECURITY AGREEMENT Recorded Aug 15, 2012
From: CYTOCHROMA DEVELOPMENT INC.
To: INEOS HEALTHCARE LIMITED
Reel/Frame 028792/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2011
From: INEOS HEALTHCARE LIMITED
To: CYTOCHROMA DEVELOPMENT INC.
Reel/Frame 027159/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 6, 2007
From: INEOS SILICAS LIMITED
To: INEOS HEALTHCARE LIMITED
Reel/Frame 019649/0357 →
CHANGE OF NAME Recorded Jan 21, 2005
From: CROSFIELD LIMITED
To: INEOS SILICAS LIMITED
Reel/Frame 016196/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2000
From: ROBERTS, NORMAN BRYSON; WEBB, MAURICE; RANKIN, BENJAMIN JOSEPH
To: CROSFIELD LIMITED
Reel/Frame 010973/0173 →
Priority Claims (1)
GB 9720061 · Sep 19, 1997 · national